

FORM-PTO-1390
(Rev. 5-93)

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

ATTORNEY'S DOCKET NUMBER

**TRANSMITTAL LETTER TO THE UNITED STATES
DESIGNATED/ELECTED OFFICE (DO/EO/US)
CONCERNING A FILING UNDER 35 U.S.C. 371**

1300-1-007

U.S. APPLICATION NO. (if known, see 37 C.F.R. 1.5)

09/674722INTERNATIONAL APPLICATION NO.
PCT/GB99/01417INTERNATIONAL FILING DATE
May 6, 1999PRIORITY DATE CLAIMED
May 6, 1998TITLE OF INVENTION
CHIMERIC RECEPTORS

APPLICANT(S) FOR DO/EO/US

Alastair David Griffiths LAWSON; and Helene Margaret FINNEY

Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:

1. ☒ This is a **FIRST** submission of items concerning a filing under 35 U.S.C. 371.
2. ☐ This is a **SECOND** or **SUBSEQUENT** submission of items concerning a filing under 35 U.S.C. 371.
3. ☒ This express request to begin national examination procedures (35 U.S.C. 371(f)) at any time rather than delay examination until the expiration of the applicable time limit set in 35 U.S.C. 371(b) and the PCT Articles 22 and 39(1).
4. ☒ A proper Demand for International Preliminary Examination was made by the 19th month from the earliest claimed priority date.
5. ☒ A copy of the International Application as filed (35 U.S.C. 371(c)(2))
 - a. ☒ is transmitted herewith (required only if not transmitted by the International Bureau).
 - b. ☒ has been transmitted by the International Bureau.
 - c. ☐ is not required, as the application was filed in the United States Receiving Office (RO/US)
6. ☒ A translation of the International Application into English (35 U.S.C. 371(c)(2)).
7. ☒ Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3))
 - a. ☒ are transmitted herewith (required only if not transmitted by the International Bureau).
 - b. ☐ have been transmitted by the International Bureau.
 - c. ☐ have not been made; however, the time limit for making such amendments has NOT expired.
 - d. ☐ have not been made and will not be made.
8. ☒ A translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)).
9. ☒ An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)).
10. ☒ A translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)).

Items 11. to 16. below concern other document(s) or information included:

11. ☐ An Information Disclosure Statement under 37 CFR 1.97 and 1.98.
12. ☒ An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.
13. ☒ A FIRST preliminary amendment.
☐ A SECOND or SUBSEQUENT preliminary amendment.
14. ☐ A substitute specification.
15. ☐ A change of power of attorney and/or address letter.
16. ☒ Other items or information:

Seven (7) Sheets of Formal Drawings; International Search Report; Preliminary Examination Report; Written Opinion

EXPRESS MAIL "MAILING CERTIFICATE NO.": EL684491585US DATE OF DEPOSIT: NOVEMBER 6, 2000

U.S. APPLICATION NO. 09/674722		INTERNATIONAL APPLICATION NO. PCT/GB99/01417		ATTORNEY'S DOCKET NUMBER 1300-1-007	
---------------------------------------	--	---	--	--	--

17. <input checked="" type="checkbox"/> The following fees are submitted:	CALCULATIONS	PTO USE ONLY																
Basic National Fee (37 CFR 1.492(a)(1)-(5)): Search Report has been prepared by the EPO or JPO \$860.00 International preliminary examination fee paid to USPTO (37 CFR 1.492) \$690.00 No international preliminary examination fee paid to USPTO (37 CFR 1.492) but international search fee paid to USPTO (37 CFR 1.445(a)(2)) \$710.00 Neither international preliminary examination fee (37 CFR 1.492) nor international search fee (37 CFR 1.445(a)(2)) paid to USPTO \$1000.00 International preliminary examination fee paid to USPTO (37 CFR 1.492) and all claims satisfied provisions of PCT Article 33(2)-(4) \$ 100.00 <div style="text-align: right;">ENTER APPROPRIATE BASIC FEE AMOUNT =</div>																		
Surcharge of \$130.00 for furnishing the oath or declaration later than months from the earliest claimed priority date (37 CFR 1.492(e)). <input type="checkbox"/> 20 <input type="checkbox"/> 30	\$																	
<table border="1" style="width:100%; border-collapse: collapse;"> <tr> <th style="width:20%;">Claims</th> <th style="width:20%;">Number Filed</th> <th style="width:20%;">Number Extra</th> <th style="width:20%;">Rate</th> </tr> <tr> <td>Total Claims</td> <td>18 -20 =</td> <td>0</td> <td>X \$ 18.00</td> </tr> <tr> <td>Independent Claims</td> <td>2 -3 =</td> <td>0</td> <td>X \$ 80.00</td> </tr> <tr> <td colspan="3">Multiple dependent claim(s) (if applicable)</td> <td>+ \$270.00</td> </tr> </table>	Claims	Number Filed	Number Extra	Rate	Total Claims	18 -20 =	0	X \$ 18.00	Independent Claims	2 -3 =	0	X \$ 80.00	Multiple dependent claim(s) (if applicable)			+ \$270.00	\$	
Claims	Number Filed	Number Extra	Rate															
Total Claims	18 -20 =	0	X \$ 18.00															
Independent Claims	2 -3 =	0	X \$ 80.00															
Multiple dependent claim(s) (if applicable)			+ \$270.00															
TOTAL OF ABOVE CALCULATIONS =	\$	860.00																
Reduction for 1/2 for filing by small entity, if applicable. Verified Small Entity statement must also be filed. (Note 37 CFR 1.9, 1.27, 1.28).	\$	-																
SUBTOTAL =	\$	860.00																
Processing fee of \$130.00 for furnishing the English translation later than months from the earliest claimed priority date (37 CFR 1.492(f)). <input type="checkbox"/> 20 <input type="checkbox"/> 30	\$																	
TOTAL NATIONAL FEE =	\$	860.00																
Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40.00 per property +	\$	40.00																
TOTAL FEES ENCLOSED =	\$	900.00																
	Amount to be:																	
	refunded	\$																
	charged	\$																

a. ☒ A check in the amount of \$ 900.00 to cover the above fees is enclosed.


b. ☐ Please charge my Deposit Account No. 11-1153 in the amount of \$_____ to cover the above fees. A duplicate copy of this sheet is enclosed.

c. ☒ The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account 11-1153. A duplicate copy of this sheet is enclosed.

NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.

SEND ALL CORRESPONDENCE TO:

DAVID A. JACKSON
KLAUBER & JACKSON
411 HACKENSACK AVENUE
4TH FLOOR
HACKENSACK, NEW JERSEY 07601


 SIGNATURE

NAME
David A. Jackson
REGISTRATION NUMBER 26,742

09/674722

529 Rec'd PCT/PTC 06 NOV2000

PATENT
1300-1-007

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANTS : Alastair David Griffiths LAWSON; and
Helene Margaret FINNEY

APPLICATION NO. : PCT/GB99/01417

FILED : May 6, 1999

FOR : CHIMERIC RECEPTORS

PRELIMINARY AMENDMENT

ASSISTANT COMMISSIONER FOR PATENTS
BOX PCT
WASHINGTON, D.C. 20231

Sir:

Prior to calculating the fees pursuant to the entry into the National Phase of the above-identified Application, please amend the claims as follows:

IN THE CLAIMS:

In Claim 5, line 1, delete "any of the preceding claims" and insert --Claim 1--.

In Claim 7, line 1, delete "any one of Claims 1 to 6" and insert --Claim 1--.

In Claim 8, line 1, delete "any one of Claims 1 to 7" and insert --Claim 1--.

In Claim 10, line 1, delete "any one of Claims 1 to 9" and insert --Claim 1--.

In Claim 11, line 1, delete "any of the preceding Claims" and insert --Claim 1--.

In Claim 13, line 1, delete "any one of Claims 1 to 12" and insert --Claim 1--.

In Claim 16, line 1, delete "any one of Claims 1 to 15" and insert --Claim 1--.

In Claim 18, line 1, delete "any one of" and insert --Claim 1--.

line 2, delete "Claims 1 to 17."


09/674722-06290

REMARKS

The above amendments are submitted herewith to reduce multiple dependencies and to conform the claims more closely to U.S. practice.

Entry of the foregoing amendments and early and favorable processing in the National Phase before the United States Patent and Trademark Office is courteously solicited.

Respectfully submitted,



DAVID A. JACKSON
Attorney for Applicant(s)
Registration No. 26,742

KLAUBER & JACKSON
411 Hackensack Avenue
Hackensack, NJ 07601
(201) 487-5800

05674722.062704
T02290"2242960

PATENT
1300-1-007

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANTS : Alastair David Griffiths LAWSON *et al*
SERIAL NO. : 09/674,722
FILED : November 6, 2000
FOR : CHIMERIC RECEPTORS

EXPRESS MAIL "MAILING CERTIFICATE NO.": EL806483590US
DATE OF DEPOSIT : JUNE 27, 2001

AMENDMENT

ASSISTANT COMMISSIONER FOR PATENTS
BOX PCT
WASHINGTON, DC 20231

Sir:

In accordance with 37 CFR 1.821 - 1.825, please amend the above-identified
Application as follows:

IN THE SPECIFICATION:

Please insert the sequence listing into the Application at the end of the Specification
and prior to the Claims.


REMARKS

The foregoing amendment is submitted in order to enter the sequence listing into the
Application.

09/674722-062701

Applicants request favorable consideration and entry of the Amendment and Sequence Listing submitted herewith and further and favorable processing of the present Application.

Respectfully submitted,

A handwritten signature in black ink, appearing to read 'David A. Jackson', written over a horizontal line.

DAVID A. JACKSON
Attorney for Applicant(s)
Registration No. 26,742

KLAUBER & JACKSON
411 Hackensack Avenue
Hackensack, NJ 07601
(201) 487-5800

PATENT
1300-1-007

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANTS : Alastair David Griffiths LAWSON *et al*
SERIAL NO. : 09/674,722
FILED : November 6, 2000
FOR : CHIMERIC RECEPTORS

EXPRESS MAIL "MAILING CERTIFICATE NO.": EL806483590US
DATE OF DEPOSIT : JUNE 27, 2001

STATEMENT IN SUPPORT OF THE FILING/SUBMISSION OF A
NUCLEOTIDE/AMINO ACID SEQUENCE LISTING IN
ACCORDANCE WITH 37 CFR §§1.821 - 1.825

ASSISTANT COMMISSIONER FOR PATENTS
BOX PCT
WASHINGTON, DC 20231

Dear Sir:


DAVID A. JACKSON, attorney of record, hereby states as follows:

1. I hereby state that the content of the paper and computer readable copies of the Sequence Listing submitted in accordance with 37 CFR §1.821(c) and (e), respectively, are the same.

2. I hereby state that the submission, filed in accordance with 37 CFR §1.821(g) herein does not include new matter.

3. I hereby declare that all statements made herein of the undersigned's own knowledge are true and that all statements made on information and belief are believed to be true; and further, that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Title 18 of the U.S. Code, Section 1001 and that such willful false statements may jeopardize the validity of this Application or any patent issuing thereon.

DATED: June 27, 2001



DAVID A. JACKSON
Attorney for Applicants
Registration No. 26,742

SEQUENCE LISTING

<110> Lawson, Alistair David Griffiths
Finney, Helene Margaret

<120> CHIMERIC RECEPTORS

<130> 1300-1-007

<140> 09/674,722

<141> 2000-11-06

<160> 14

<170> PatentIn Ver. 2.1

<210> 1

<211> 30

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: oligo S4501 from Figure 2

<400> 1

cgcaagcttg ccgccacat ggaatggagc

0

3

<210> 2

<211> 30

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: oligo S4502 from Figure 2

<400> 2

tggactagtt gaggcagaag acactgtcac

0

3

<210> 3

<211> 29

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: oligo S4503 from Figure 2

09674722-0000

<400> 3
cgcaagcttg cgcaccat gtctgtccc 2
9

<210> 4
<211> 32
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: oligo S4504 from Figure 2

<400> 4
tggactagtc gtacgtttta cttctacttt ag 3
2

<210> 5
<211> 70
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: oligo S4881 from Figure 2

<400> 5
cgtgccggtc ttcttgccag cgaagcccgg tgcggggcca gcgccgcgac caccaacacc 6
0
ggcgcccacc 7
0

<210> 6
<211> 72
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: oligo S4882 from Figure 2

<400> 6
gaggcggcgc ggccagcggc ggggggcgca gtgcacacga gggggctgga cttcgcggcc 6
0
gccctgattg tg 7
2

<210> 7
<211> 72
<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: oligo S4883 from Figure 2

<400> 7

cgccgctggc cgcccgct ctgggcgcag ggacaggggc tgcgacgcga tggtagggcgc 6
0
cggtggttgg gg 7
2

<210> 8

<211> 65

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: oligo S4884 from Figure 2

<400> 8

cgctggcagg aagaccggca cgaagtggct gaagtacatg atggagttgc tcagggcact 6
0
agttg 6
5

<210> 9

<211> 23

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: oligo S4885 from Figure 2

<400> 9

caactagtgc cctgagcaac tcc 2
3

<210> 10

<211> 22

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: oligo S4886 from Figure 2

<400> 10

cacaatcagg gcggccgcga ag 2
2

<210> 11
<211> 39
<212> DNA
<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: oligo S4499 from Figure 2

<400> 11
ctgcagttcg cggccgccct gattgtgctg gggggcgtc 3
9

<210> 12
<211> 45
<212> DNA
<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: oligo S4500 from Figure 2

<400> 12
gccgagctcc tatatgaatt ctcaaattggg gctacatgtc ttctg 4
5

<210> 13
<211> 34
<212> DNA
<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: oligo S4700 from Figure 2

<400> 13
tatgaattct tagcgagggg gcagggcctg catg 3
4

<210> 14
<211> 101
<212> DNA
<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: oligo S4701 from Figure 2

<400> 14
ctggacttcg cggccgccct gattgtgctg gggggcgtcg ccggcctcct gcttttcatt 6
0

gggctaggca tcttcttcag agtgaagttc agcaggagcg c
01

1

0967472224650

JA

PCT09

RAW SEQUENCE LISTING

DATE: 08/30/2001

PATENT APPLICATION: US/09/674,722

TIME: 06:45:37

Input Set : A:\USSN 09674722 Sequence listing.txt

Output Set: N:\CRF3\08302001\I674722.raw

ENTERED

FOC 2001 08 22 14:24:56

```

3 <110> APPLICANT: Lawson, Alistair David Griffiths
4   Finney, Helene Margaret
6 <120> TITLE OF INVENTION: CHIMERIC RECEPTORS
8 <130> FILE REFERENCE: 1300-1-007
10 <140> CURRENT APPLICATION NUMBER: 09/674,722
11 <141> CURRENT FILING DATE: 2000-11-06
13 <160> NUMBER OF SEQ ID NOS: 14
15 <170> SOFTWARE: PatentIn Ver. 2.1
17 <210> SEQ ID NO: 1
18 <211> LENGTH: 30
19 <212> TYPE: DNA
20 <213> ORGANISM: Artificial Sequence
22 <220> FEATURE:
23 <223> OTHER INFORMATION: Description of Artificial Sequence: oligo S4501 from Figure 2
25 <400> SEQUENCE: 1
26 cgcaagcttg ccgccaccat ggaatggagc                                     30
28 <210> SEQ ID NO: 2
29 <211> LENGTH: 30
30 <212> TYPE: DNA
31 <213> ORGANISM: Artificial Sequence
33 <220> FEATURE:
34 <223> OTHER INFORMATION: Description of Artificial Sequence: oligo S4502 from Figure 2
36 <400> SEQUENCE: 2
37 tggactagtt gaggcagaag acactgtcac                                     30
39 <210> SEQ ID NO: 3
40 <211> LENGTH: 29
41 <212> TYPE: DNA
42 <213> ORGANISM: Artificial Sequence
44 <220> FEATURE:
45 <223> OTHER INFORMATION: Description of Artificial Sequence: oligo S4503 from Figure 2
47 <400> SEQUENCE: 3
48 cgcaagcttg ccgccaccat gtctgtccc                                     29
50 <210> SEQ ID NO: 4
51 <211> LENGTH: 32
52 <212> TYPE: DNA
53 <213> ORGANISM: Artificial Sequence
55 <220> FEATURE:
56 <223> OTHER INFORMATION: Description of Artificial Sequence: oligo S4504 from Figure 2
58 <400> SEQUENCE: 4
59 tggactagtc gtacgtttta cttctacttt ag                                   32
61 <210> SEQ ID NO: 5
62 <211> LENGTH: 70
63 <212> TYPE: DNA
64 <213> ORGANISM: Artificial Sequence
66 <220> FEATURE:
67 <223> OTHER INFORMATION: Description of Artificial Sequence: oligo S4881 from Figure 2
69 <400> SEQUENCE: 5

```

RAW SEQUENCE LISTING

DATE: 08/30/2001

PATENT APPLICATION: US/09/674,722

TIME: 06:45:37

Input Set : A:\USSN 09674722 Sequence listing.txt

Output Set: N:\CRF3\08302001\I674722.raw

70 cgtgccggtc ttctgccag cgaagcccgg tgcggggcca gcgccgcgac caccaacacc 60
 71 ggcccccacc 70
 73 <210> SEQ ID NO: 6
 74 <211> LENGTH: 72
 75 <212> TYPE: DNA
 76 <213> ORGANISM: Artificial Sequence
 78 <220> FEATURE:
 79 <223> OTHER INFORMATION: Description of Artificial Sequence: oligo S4882 from Figure 2
 81 <400> SEQUENCE: 6
 82 gaggcggcgc ggccagcggc ggggggcgca gtgcacacga gggggctgga cttcgcggcc 60
 83 gccctgattg tg 72
 85 <210> SEQ ID NO: 7
 86 <211> LENGTH: 72
 87 <212> TYPE: DNA
 88 <213> ORGANISM: Artificial Sequence
 90 <220> FEATURE:
 91 <223> OTHER INFORMATION: Description of Artificial Sequence: oligo S4883 from Figure 2
 93 <400> SEQUENCE: 7
 94 cgccgctggc cgcgcgcct ctgggcgcag ggacaggggc tgcgacgcga tgggtgggcgc 60
 95 cgggtgttgt gg 72
 97 <210> SEQ ID NO: 8
 98 <211> LENGTH: 65
 99 <212> TYPE: DNA
 100 <213> ORGANISM: Artificial Sequence
 102 <220> FEATURE:
 103 <223> OTHER INFORMATION: Description of Artificial Sequence: oligo S4884 from Figure
 105 <400> SEQUENCE: 8
 106 cgctggcagg aagaccggca cgaagtggct gaagtacatg atggagttgc tcagggcact 60
 107 agttg 65
 109 <210> SEQ ID NO: 9
 110 <211> LENGTH: 23
 111 <212> TYPE: DNA
 112 <213> ORGANISM: Artificial Sequence
 114 <220> FEATURE:
 115 <223> OTHER INFORMATION: Description of Artificial Sequence: oligo S4885 from Figure
 117 <400> SEQUENCE: 9
 118 caactagtgc cctgagcaac tcc 23
 120 <210> SEQ ID NO: 10
 121 <211> LENGTH: 22
 122 <212> TYPE: DNA
 123 <213> ORGANISM: Artificial Sequence
 125 <220> FEATURE:
 126 <223> OTHER INFORMATION: Description of Artificial Sequence: oligo S4886 from Figure
 128 <400> SEQUENCE: 10
 129 cacaatcagg gcggccgcga ag 22
 131 <210> SEQ ID NO: 11
 132 <211> LENGTH: 39
 133 <212> TYPE: DNA
 134 <213> ORGANISM: Artificial Sequence

RAW SEQUENCE LISTING

DATE: 08/30/2001

PATENT APPLICATION: US/09/674,722

TIME: 06:45:37

Input Set : A:\USSN 09674722 Sequence listing.txt

Output Set: N:\CRF3\08302001\I674722.raw

136 <220> FEATURE:

137 <223> OTHER INFORMATION: Description of Artificial Sequence: oligo S4499 from Figure

139 <400> SEQUENCE: 11

140 ctgcagttcg cggccgcccct gattgtgctg gggggcgctc 39

142 <210> SEQ ID NO: 12

143 <211> LENGTH: 45

144 <212> TYPE: DNA

145 <213> ORGANISM: Artificial Sequence

147 <220> FEATURE:

148 <223> OTHER INFORMATION: Description of Artificial Sequence: oligo S4500 from Figure

150 <400> SEQUENCE: 12

151 gccgagctcc tatatgaatt ctcaaatggg gctacatgctc ttctg 45

153 <210> SEQ ID NO: 13

154 <211> LENGTH: 34

155 <212> TYPE: DNA

156 <213> ORGANISM: Artificial Sequence

158 <220> FEATURE:

159 <223> OTHER INFORMATION: Description of Artificial Sequence: oligo S4700 from Figure

161 <400> SEQUENCE: 13

162 tatgaattct tagcgagggg gcagggcctg catg 34

164 <210> SEQ ID NO: 14

165 <211> LENGTH: 101

166 <212> TYPE: DNA

167 <213> ORGANISM: Artificial Sequence

169 <220> FEATURE:

170 <223> OTHER INFORMATION: Description of Artificial Sequence: oligo S4701 from Figure

172 <400> SEQUENCE: 14

173 ctggacttcg cggccgcccct gattgtgctg gggggcgctc cgggcctcct gcttttcatt 60

174 gggctaggca tcttcttcag agtgaagttc agcaggagcg c 101

VERIFICATION SUMMARY

DATE: 08/30/2001

PATENT APPLICATION: US/09/674,722

TIME: 06:45:38

Input Set : A:\USSN 09674722 Sequence listing.txt

Output Set: N:\CRF3\08302001\I674722.raw

09674722.162701
10/22/01 22/4/960

09 / 674722

CHIMERIC RECEPTORS

5 This invention relates to chimeric receptors, to DNA coding therefor and to the use of the receptors in medicine.

10 Chimeric receptors have been designed to target cells such as T-cells to other cells expressing antigen on their cell surface. Binding of antigen to the receptor in the correct context triggers a series of intracellular events leading to activation of the receptor bearing cell. Activation may lead to an increase in proliferation; expression of cytokines, with for example pro or anti-inflammatory responses; stimulation of cytolytic activity, differentiation or other effector functions; antibody secretion; phagocytosis; tumour infiltration and/or increased adhesion. Clearly such activation may have
15 therapeutic benefits and chimeric receptors which can facilitate this are of use in the treatment of a number of diseases or disorders.

20 Previously described chimeric receptors provide antigen recognition either in a single chain, for example as in a single chain, Fv or CD4, linked to an intracellular signalling region [Eshhar, Z *et al* (1993) Proc. Natl. Acad. Sci. USA 90, 720; Stancovski, I *et al* (1993) J. Immunol. 151, 6577; Hwu, P *et al* (1993) J. Exp. Med. 178, 361; Brocker, T *et al* (1993) Eur. J. Immunol. 23, 1435; Moritz, D. *et al* (1994) Proc. Natl. Acad. Sci. USA, 91, 4318; Roberts, M. *et al* (1994) Blood 84, 2878; Hwu, P *et al* (1995) Cancer
25 Res. 55, 3369; Tran, A-C *et al* (1995) J. Immunol. 155, 1000; Hekele, A *et al* (1996) Int. J. Cancer 68, 232; Altenschmidt, U *et al* (1996) Clin. Cancer Res. 2, 1001; Brocker, T *et al* (1996) Eur. J. Immunol. 26, 1770; Weitjens, M *et al* (1996) J. Immunol. 157, 836; Alvarez-Vallina, L and Hawkins, R E (1996) Eur. J. Immunol. 26, 2304], or in two chains as in V_L-
30 TCR α with V_H-TCR β or V_H-TCR α with V_L-TCR β but with no intracellular signalling sequences attached [Kuwana, Y *et al* (1987) Biochem. Biophys. Res. Commun. 149, 960; Gross, G *et al* (1989) Proct. Natl. Acad. Sci. USA 86, 10024].

35 The mechanisms by which such receptors convert the extracellular binding event into intracellular signalling are largely unclear, and are likely to

09674722

involve clustering and association with endogenous cellular effector molecules. One disadvantage in their design is that there is no inherent mechanism to prevent constitutive activation in the absence of antigenic stimulation. This is undesirable since it can lead to inappropriate activation of a cell. Another problem with previously described chimeric receptors is that they are susceptible to signalling on binding soluble antigen. This limits their usefulness in the treatment of some disorders, for example in tumour therapy where many cell associated tumour antigens are also shed into the vascular system and can therefore induce inappropriate signalling by the chimeric receptor away from the tumour site.

The present invention provides an improved chimeric receptor which minimises constitutive activation in the absence of antigen and is less readily triggered by soluble antigen than previously described designs. In one particularly advantageous form the receptor according to the invention includes a mechanism whereby multiple signalling components can be localised on binding of antigen to act cooperatively to efficiently generate an intracellular signal.

The improved chimeric receptors according to the invention generally feature two or more polypeptide chains each of which contains an extracellular ligand association domain attached to a signalling domain through a transmembrane and optionally one or more spacer domains. The ligand association domains are capable of acting cooperatively with each other in the presence of ligand to form a ligand binding site. Each chain may be expressed so that it locates in a cell membrane with an orientation in which the association domain is extracellular and the signalling domain is intracellular. By careful selection of the ligand association domains and non-associating spacer and/or transmembrane domains each polypeptide chain can be expressed independently and will remain largely unassociated with the other(s) in the absence of ligand. The presence of ligand, especially cell surface expressed ligand induces a stable interaction between the ligand association domains, specifically stabilising a close spatial proximity of the polypeptide chains, and facilitating interaction between the intracellular signalling domains. The

signalling domains can be selected such that one forms a substrate for the other, thus increasing the efficiency of the signalling event.

The chimeric receptor according to the invention can be expressed in a host cell transformed with DNA coding for each polypeptide chain. Thus according to one aspect of the invention we provide DNA coding for a chimeric receptor containing two or more independent polypeptide chains each of said chains comprising in a N- to C-terminus sequence:

- (1) an extracellular ligand association domain;
 - 10 (2) a transmembrane domain; and
 - (3) one or more intracellular domains;
- provided that at least two of said domains in one chain are not naturally fused to each other.

- 15 For the avoidance of doubt, the term "not naturally fused" as used herein is intended to mean that two or more domains are not linked in a way which generates a polypeptide found in nature. Clearly, in this way, naturally occurring receptors are intended to be excluded from the invention. Providing that at least two domains are not naturally fused in
- 20 this way other domains, where desired, may be linked in a naturally occurring arrangement.

As used herein the term extracellular ligand association domain is intended to mean any oligo- or polypeptide which is capable of interacting with cell surface molecules expressed on a target or host cell.

25

Thus the domain may be chosen to recognise a surface marker expressed on target cells associated with a disease state such as for example those associated with virally infected cells; bacterially infected cells; cancer cells, such as the bombesin receptor expressed on lung tumour cells, carcinoembryonic antigen, polymorphic epithelial mucin and CD33; cell surface adhesion molecules; inflammatory cells present in autoimmune disease; or a T-cell receptor or antigen giving rise to autoimmunity.

30

35 Alternatively, the association ligand domain may be chosen such that it interacts with one or more of the other ligand association domains of the

chimeric receptor expressed by the host cell to achieve multiply-associated domains capable of recognising a surface marker expressed on a target cell as just described.

- 5 Particularly useful ligand association domains include parts of receptors associated with binding to cell surface associated molecules and especially include an antibody variable region (V_H or V_L) domain, a T-cell receptor variable region domain ($TCR\alpha$, $TCR\beta$, $TCR\gamma$, $TCR\delta$) or a chain selected from $CD8\alpha$, $CD8\beta$, $CD11a$, $CD11b$, $CD11c$, $CD18$, $CD29$,
10 $CD49a$, $CD49b$, $CD49c$, $CD49d$, $CD49e$, $CD49f$, $CD61$, $CD41$ or $CD51$. Fragments of these domains and chains may be used where appropriate.

- Each association domain in the chimeric receptor may be the same, although desirably the association domains are structurally different. In
15 one preferred arrangement, the domains are able to act cooperatively with each other to form a ligand binding site. Particular examples include a V_H domain paired with a V_L domain, two or more $TCR\alpha$, $TCR\beta$, $TCF\gamma$, and/or $TCR\delta$ domains, a $CD8\alpha$ or β homo- or heterodimer, $CD18$ paired with one or more of $CD11a$, b , or c , $CD29$ paired with one or more of $CD49a$, b , c ,
20 d , e , or f , and $CD61$ paired with $CD41c$ and/or $CD51$.

- In binding to the ligand each association domain moves to form a ligand binding site and in so doing establishes a close spatial proximity of the intracellular domains which form the C-terminal regions of the polypeptide
25 chains which constitute the chimeric receptor. Particularly useful ligand association domains include antibody V_H and V_L domains and fragments thereof, especially in a two chain receptor where one of the association domains is a V_H domain or a fragment thereof and the other is a V_L domain or a fragment thereof.

30

- As used herein the term intracellular domain is intended to mean any oligo- or polypeptide which can participate in the transduction of a signal which results in direct or indirect activation of one or more intracellular messenger systems. Particular intracellular messenger systems include
35 for example one or more kinase pathways such as those involving tyrosine kinase, protein kinase C or MAP kinase; G-protein or phospholipase

mediated pathways; calcium mediated pathways; and pathways involving synthesis of a cytokine such as an interleukin e.g. IL-2, including NFAT, and cAMP mediated pathways.

- 5 Each intracellular domain may be derived from one or more naturally occurring polypeptide signalling sequences. Examples of suitable sequences include, for example sequences derived from the T-cell receptor such as all or part of the zeta, eta or epsilon chain; CD28; CD4; CD8; the γ chain of a Fc receptor; or signalling components from a
- 10 cytokine receptor e.g. interleukin, TNF and interferon receptors, a colony stimulating factor receptor e.g. GMCSF, a tyrosine kinase e.g. ZAP-70, fyn, lck, Itk and syk and binding domains thereof; an adhesion molecule e.g. LFA-1 and LFA-2, B29, MB-1, CD3 delta, CD3 gamma, CD5 or CD2.
- 15 At least one component in each intracellular domain will be capable of interacting cooperatively with one or more other components in other intracellular domains. Cooperative interaction includes for example association of two or more components to form a substrate capable of participating in one of the intracellular messenger systems described
- 20 above. Preferably however cooperative interaction means one of the components acting as a substrate for one or more others such that the substrate initiates a signalling event. This can either lead to an activation or down-regulation of signalling cascade. A particular example of this type of cooperative interaction may be obtained when one of the components in
- 25 an intracellular domain is derived from a CD4 intracellular chain containing the lck binding domain and a component in the other intracellular domain is a zeta chain derived from the T-cell receptor. Binding of ligand to the chains of the chimeric receptor causes association of lck with zeta facilitating phosphorylation of the zeta ARAM tyrosine residues, an early
- 30 event in signal generation.

- The transmembrane domain in each polypeptide chain of the chimeric receptor generally serves to anchor each chain to the cell membrane of the host cell. Transmembrane domains may in general be any oligo- or
- 35 polypeptide and may be derived from a wide variety of sources such as all or part of the alpha, beta or zeta chain of the T-cell receptor, CD28, CD8,

CD4, CD3 ϵ , CD45 and members of the tetraspan family e.g. CD9, CD37 a cytokine receptor, e.g. an interleukin receptor, TNF receptor, or interferon receptor, or a colony stimulating factor receptor, e.g. GMCSF.

- 5 Whatever the derivation of each transmembrane domain it will be desirably chosen or modified to minimise its constitutive association with any other domain in the chimeric receptor but to allow association of the receptor polypeptide chains when ligand is bound by one or more extracellular association domains. This reduces undesirable random
10 signal generation by ensuring that the intracellular domains only interact when ligand is bound by the extracellular association domains. This forms an important aspect of the design of the receptors of the invention.

- In addition to the selection of appropriate transmembrane domains, the
15 ability of each receptor polypeptide chain to remain unassociated except in the presence of bound ligand may be enhanced by incorporating a spacer region between each extracellular association domain and transmembrane domain. Thus, according to a preferred aspect of the invention we provide DNA coding for a chimeric receptor containing two or more independent
20 polypeptide chains, each of said chains comprising in N- to C-terminus sequence:

- (1) an extracellular ligand association domain;
- (2) a spacer domain;
- (3) a transmembrane domain; and
- 25 (4) one or more intracellular domains; provided that at least two of said domains in one chain are not naturally fused to each other.

- The term spacer domain as used herein generally means any oligo- or polypeptide serving to link the association and transmembrane domains in
30 each chain. Spacer domains may for example comprise up to 300 amino acids, preferably 20 to 100 amino acids and most preferably 25 to 50 amino acids.

- Spacers may be derived from all or part of naturally occurring molecules
35 such as from all or part of the extracellular region of CD8, CD4 or CD28; or all or part of an antibody constant region, including the hinge region. All

or part of natural spacing components between functional parts of intracellular signalling molecules, for example spacers between ITAMS (immunoreceptor tyrosine based activation motifs) may also be used. Alternatively the spacer may be a non-naturally occurring sequence.

5

In order to minimise the constitutive association of transmembrane and/or spacer domains, non-naturally associating domains may initially be selected and/or domains may be modified to reduce association. This may be achieved by deleting, changing or otherwise modifying amino acids of naturally occurring sequences in the transmembrane and/or spacer domains which have side chains capable of covalently or non-covalently interacting with the side chains of amino acids in the other chain. Particular examples of amino acids of these types include cysteine residues, charged amino acids or amino acids such as serine or threonine within potential glycosylation sites.

10

15

The DNA according to the invention will additionally contain coding sequences for a signal component for each of the chains of the chimeric receptor to enable each chain to be transported to the host cell membrane. Each signal will be attached to the N-terminus of the association domain of each chain. The signal component may be that naturally associated with the association domain or may be derived from other sources. Examples of secretion signals include immunoglobulin signal sequences.

20

25

The signal, association, spacer, transmembrane and intracellular domains of each chain in the chimeric receptor are preferably derived from or based on human sequences.

Particularly useful DNA according to the invention is that coding for a chimeric receptor containing two independent polypeptide chains as described herein. In receptors of this type, one of the chains preferably has a ligand association domain which is a V_H domain or a fragment thereof, and the other has a ligand association domain which is a V_L domain or a fragment thereof.

30

35

DNA coding sequences for use in the invention are widely available in the literature and from databases. The DNA may be obtained from readily available DNA sources for example commercially available cDNA or cDNA libraries using standard molecular biology and/or chemistry procedures, for example by use of the polymerase chain reaction (PCR), oligonucleotide directed mutagenesis or oligonucleotide directed synthesis techniques, enzymatic cleavage or enzymatic filling in of gapped oligonucleotides. Such techniques are described by Maniatis *et al* in Molecular Cloning, Cold Spring Harbor Laboratory, New York 1989, and in particular in the Examples hereinafter.

The DNA may be used in association with a carrier. The carrier may be a vector or other carrier suitable for introduction of the DNA *ex-vivo* or *in-vivo* into target cells and/or target host cells. Examples of suitable vectors include viral vectors such as retroviruses, adenoviruses, adenoassociated viruses, EBV, and HSV, and non-viral vectors, such as liposomal vectors and vectors based on DNA condensing agents for example cationic lipids such as those described in International Patent Specifications Nos. WO96/10038, WO97/18185, WO97/25329, WO97/30170 and WO97/31934. Where appropriate, the vector may additionally include promoter/regulatory sequences and/or replication functions from viruses such as retrovirus LTRs, AAV repeats, SV40 and hCMV promoters and/or enhancers, splicing and polyadenylation signals; EBV and BK virus replication functions. Tissue specific regulatory sequences such as the TCR- α promoter, E-selectin promoter and the CD2 promoter and locus control region may also be used. Alternatively the carrier may be an antibody.

Each DNA molecule coding for a polypeptide chain of the chimeric receptor may be incorporated into different carriers as described above. Preferably however the DNA is incorporated into the same carrier. For this the DNA may be located for example on separate plasmids or may be advantageously part of a single plasmid additionally containing one or more promoter and/or regulatory sequences and or replication functions as just described. Thus the invention extends to a plasmid comprising DNA coding for a chimeric receptor according to the invention. Particularly

useful plasmids of this type include plasmid pHMF374 described in the Examples hereinafter and analogous plasmids containing other ligand association, spacer and/or transmembrane, and intracellular domains to those specified therein.

5

For ex-vivo use, the DNA of the invention may be introduced into effector cells removed from the target host using methods well known in the art e.g. transfection, transduction, biolistics, protoplast fusion, calcium phosphate precipitated DNA transformation, electroporation, cationic lipofection, or targeted liposomes. The effector cells are then reintroduced into the host using standard techniques.

10

A wide variety of target hosts may be employed according to the present invention such as, for example, mammals and, especially, humans.

15

Examples of suitable effector cells include cells associated with the immune system such as lymphocytes e.g. cytotoxic T-lymphocytes, tumour infiltrating lymphocytes, natural killer cells, neutrophils, basophils or T-helper cells; dendritic cells, B-cells, haematopoietic stem cells, macrophages, monocytes or NK cells. The use of cytotoxic T-lymphocytes is especially preferred.

20

The DNA according to the invention is particularly suitable for in vivo administration. It may be in one preferred example in the form of a targeted carrier system in which a carrier as described above is capable of directing the DNA to a desired effector cell. Particular examples of such targeted delivery systems include targeted-naked DNA, targeted liposomes encapsulating and/or complexed with the DNA, targeted retroviral systems and targeted condensed DNA such as protamine and polylysine condensed DNA.

25

30

Targeting systems are well known in the art and include using, for example, antibodies or fragments thereof against cell surface antigens expressed on target cells in vivo such as CD8; CD16; CD4; CD3; selectins e.g. E-selectin; CD5; CD7; CD34; activation antigens e.g. CD69 and IL-

35

2R. Alternatively, other receptor - ligand interactions can be used for targeting e.g. CD4 to target HIV_{gp160} - expressing target cells.

5 In general the use of antibody targeted DNA is preferred, particularly antibody targeted naked DNA, antibody targeted condensed DNA and especially antibody targeted liposomes. Particular types of liposomes which may be used include for example pH-sensitive liposomes where linkers cleaved at low pH may be used to link the antibody to the liposome. Cationic liposomes which fuse with the cell membrane and deliver the
10 recombinant chimeric receptor DNA according to the invention directly into the cytoplasm may also be used. Liposomes for use in the invention may also have hydrophilic groups attached to their surface to increase their circulating half-life such as for example polyethylene glycol polymers. There are many examples in the art of suitable groups for attaching to
15 liposomes or other carriers; see for example International Patent Specifications Nos. WO 88/04924, WO 90/09782, WO 91, 05545, WO 91/05546, WO 93/19738, WO 94/20073 and WO 94/22429. The antibody or other targeting molecule may be linked to the DNA, condensed DNA or liposome using conventional readily available linking groups and reactive
20 functional groups in the antibody e.g. thiols, or amines and the like, and in the DNA or DNA containing materials.

Non-targeted carrier systems may also be used and in these targeted expression of the DNA is advantageous. Targeted expression of the DNA
25 may be achieved for example by using T-cell specific promoter systems such as the zeta promoter and CD2 promoter and locus control region, CD4, CD8, TCR α and TCR β promoters, cytokine promoters such as the IL2 promoter and the perforin promoter.

30 The DNA according to the invention may be used ex vivo and in a further aspect the invention provides effector cells transfected with DNA according to the invention. The effector cells may be any of those previously described above which are suitable for ex vivo use and are preferably T-cells most preferably cytotoxic T-cells.

The DNA according to the invention may take the form of a pharmaceutical composition. It may be a therapeutic or diagnostic composition and may take any suitable form suitable for administration. Preferably it will be in a form suitable for parenteral administration e.g. by
5 injection or infusion, for example by bolus injection or continuous infusion or particle mediated injection. Where the composition is for injection or infusion, it may take the form of a suspension, solution or emulsion in an oily or aqueous vehicle and it may contain formulatory agents such as suspending, preservative, stabilising and/or dispersing agents.
10 Alternatively, the composition may be in dry form, for reconstitution before use with an appropriate sterile liquid. For particle mediated administration the DNA may be coated on particles such as microscopic gold particles.

If the composition is suitable for oral administration the formulation may
15 contain, in addition to the active ingredient, additives such as: starch - e.g. potato, maize or wheat starch or cellulose - or starch derivatives such as microcrystalline cellulose; silica; various sugars such as lactose; magnesium carbonate and/or calcium phosphate. It is desirable that, if the formulation is for oral administration it will be well tolerated by the patient's
20 digestive system. To this end, it may be desirable to include in the formulation mucus formers and resins. It may also be desirable to improve tolerance by formulating the compositions in a capsule which is insoluble in the gastric juices. It may also be preferable to include the composition in a controlled release formulation.

25
The DNA according to the invention is of use in medicine and the invention extends to a method of treatment of a human or animal subject, the method comprising administering to the subject an effective amount of a DNA delivery system described above. The exact amount to be used will
30 depend on the ages and condition of the patient, the nature of the disease or disorder and the route of administration, but may be determined using conventional means, for example by extrapolation of animal experiment derived data. In particular, for ex vivo use the number of transfected effector cells required may be established by ex vivo transfection and re-
35 introduction into an animal model of a range of effector cell numbers.

Similarly the quantity of DNA required for *in vivo* use may be established in animals using a range of DNA concentrations.

5 The DNA according to the invention may be useful in the treatment of a number of diseases or disorders. Such diseases or disorders may include those described under the general headings of infectious diseases, e.g. HIV infection; inflammatory disease/autoimmunity e.g. rheumatoid arthritis, osteoarthritis, inflammatory bowel disease; cancer; allergic/atopic diseases e.g. asthma, eczema; congenital e.g. cystic fibrosis, sickle cell
10 anaemia; dermatologic, e.g. psoriasis; neurologic, e.g. multiple sclerosis; transplants e.g. organ transplant rejection, graft-versus-host disease; metabolic/idiopathic disease e.g. diabetes.

15 The following Example illustrates the invention. In the Example the results show that the two chain chimeric receptor is not constitutively activated, in that no IL-2 was produced in the absence of target cells (HL60) or in the presence of cells not expressing specific antigen (NSO), and can be triggered to produce IL-2 only in the presence of cells expressing specific antigen (HL60 or NSO.CD33).

20

EXAMPLE

CONSTRUCTION OF CHIMERIC RECEPTOR GENES

25 Each component of the chimeric receptor was either PCR cloned or PCR assembled by standard techniques (PCR Protocols, Innis *et al* (1990) Academic Press Inc.) and sub-cloned in a cassette format into pBluescript KS+ (Stratagene), see Figure 1. Oligonucleotides (oligos) are described in Figure 2.

30 a) **VL Cassette**

The variable region of the light chain of the human engineered antibody, hP67 (engineered according to International Patent Specification WO91/09967) was PCR cloned with oligos S4503 and S4504. S4503 introduces a 5' Hind III site and S4504 a 3' Spe I site. The PCR product
35 was restricted with Hind III and Spe I and subcloned into pBluescript KS+.

b) **Vh Cassette**

The variable region of the heavy chain of the human engineered antibody, hP67 (engineered according to International Patent Specification WO91/0997) was PCR cloned with oligos S4501 and S4502. S4501 introduces a 5' Hind III site and S4502 a 3' Spe I site. The PCR product was restricted with Hind III and Spe I and subcloned into pBluescript KS+.

c) **CD8* Spacer Cassette**

The CD8* spacer cassette was PCR assembled using overlapping oligos: S4881, S4882, S4883, S4884, S4885 and S4886. The PCR product was restricted with Spe I and Not I and subcloned into pBluescript KS+.

d) **CD4 TM / CD4 Cassette**

The CD4 transmembrane and intracellular components were PCR cloned from human Leukocyte cDNA (Clonotech) with oligos S4499 and S4500. S4499 introduces a 5' Not I site and S4500 introduces a 3'EcoR I and Sac I site. The PCR product was restricted with Not I and Sac I and subcloned into pBluescript KS+.

e) **CD4 TM / TCR Zeta Cassette**

The intracellular component of TCR Zeta was PCR cloned from human Leukocyte cDNA (Clonotech) with oligos S4701 and S4700. S4701 is a long oligo which introduces both a 5' Not I site and the CD4 transmembrane component. S4700 introduces a 3' EcoR I site.

The PCR product was restricted with Not I and EcoR I and substituted for the CD4 TM / CD4 cassette in pBluescript KS+.

All of the above cassettes were sequenced (Applied Biosystems, Taq DyeDeoxy Terminator Cycle Sequencing, Part Number 901497) in pBluescript KS+ prior to cloning into expression vectors.

These cassettes were assembled using standard Molecular Biology techniques to construct the following Separate Chain chimeric receptors which when associated have the potential for human CD33 specificity.

a) VH / CD8* / CD4 TM / CD4

The VH / CD8* / CD4 TM / CD4 chimeric receptor consists of the variable region of the heavy chain of the human engineered antibody P67 linked via an extracellular spacer based upon part of human CD8 hinge to the transmembrane and intracellular components of human CD4.

The extracellular spacer consists of residues 95 to 159 of human CD8 (with the following amino acid substitution:- Cys (143) changed to Ala to remove a potential disulphide bond and Thr (117, 118 and 119) changed to Gly, Ala, Gly respectively to reduce potential negative charge) followed by a Gly residue to introduce a restriction site [Sukhatme *et al*, (1985) Cell 40, 591-597]. The CD4 transmembrane and intracellular component consists of residues 375 to 435 [Maddon *et al*, (1985) Cell, 42, 93-104].

15 b) VI / CD8* / CD4 TM / TCR Zeta

The VI / CD8* / CD4 TM / TCR Zeta chimeric receptor consists of the variable region of the light chain of the human engineered antibody P67 linked via an extracellular spacer based upon part of human CD8 hinge to the transmembrane and intracellular components of human CD4.

The extracellular spacer consists of residues 95 to 159 of human CD8 (with the following amino acid substitution:- Cys (143) changed to Ala to remove a potential disulphide bond and Thr (117, 118 and 119) changed to Gly, Ala, Gly respectively to reduce potential negative charge) followed by a Gly residue to introduce a restriction site [Sukhatme *et al* (1985) Cell, 40, 591-597]. The CD4 transmembrane component consists of residues 375 to 395 [Sukhatme *et al*, (1985), Cell, 40, 591-597]. The TCR Zeta intracellular component consists of residues 31 to 142 [Weissman *et al*, (1988) PNAS, 85, 9709-9713. Moingeon *et al* (1990) Eur. J. Immunol, 20, 1741-1745].

ANALYSIS OF SEPARATE CHAIN CHIMERIC RECEPTORS EXPRESSED IN JURKAT CELLS

a) Construction of expression plasmids

35 Chimeric receptor constructs were subcloned from pBluescript KS+ into the expression vector pEE6hCMV.ne [Bebbington (1991), Methods 2, 136-

145] on a Hind III to EcoR I restriction fragment to generate plasmids pHMF367 and pHMF370 (see Figure 3). An expression vector was constructed expressing both separate chain chimeric receptor genes by subcloning a Bgl to BamH I fragment consisting of hCMV promoter, VI / CD8* / CD4 TM / TCR Zeta and SV40 poly A site into the BamH I site of pHMF367. This double receptor plasmid is pHMF374 (see Figure 3).

b) **Construction of Jurkat cell lines**

Plasmids were linearised and transfected into Jurkat E6.1 cells (ECACC) by electroporation using a Bio-Rad Gene Pulser. 30µg of DNA per 1 x 10⁷ cells were given two pulses of 100v, 3µF in 1ml PBS. Cells were left to recover overnight in non-selective media before being selected and cultured in media supplemented with the antibiotic G418 at 2mg/ml. After approximately four weeks cells were ready for IL-2 production analysis.

c) **Analysis of antigen-specific IL-2 production**

1 x 10⁵ Jurkat cells expressing either control plasmid, pEE6hCMV.ne (J. control) or double receptor plasmid, pHMF374 (J.VL/VH) were incubated overnight with target cells at various effector (E): target cell (T) ratios in a 96 well plate (Falcon) at 37°C/8% CO₂.

Target cells used were : the human myelocytic cells line, HL60 which expresses CD33 or the mouse myeloma, NSO transfected with either a control plasmid or one expressing human CD33. After 20-24 hours cells were centrifuged and supernatant assayed for IL-2 (Quantikine kit, R & D Systems).

RESULTS

Figure 4 shows IL-2 production from Jurkat cells expressing VI / Vh separate chain chimeric receptors challenged with CD33 positive HL60 target cells. Jurkat cells expressing a control plasmid produced no IL-2 when incubated with HL60 cells, and Jurkat transfectants expressing the separate chain chimeric receptors did not constitutively produce IL-2 in the absence of target cells. IL-2 was specifically produced from transfectants on challenge with antigen bearing target cells, with the amount of IL-2 decreasing as the E : T ratio was increased.

- Figure 5 shows the antigen specificity of IL-2 production from Jurkat transfectants expressing separate chain chimeric receptors. NSO cells transfected with a control plasmid failed to elicit an IL-2 response from
- 5 Jurkat cells expressing separate chain chimeric receptors, however on challenge with NSO cells that had been transfected with a CD33 plasmid and shown to express cell surface CD33, Jurkat transfectants expressing separate chain chimeric receptors produced IL-2.

CLAIMS

1. DNA coding for a chimeric receptor containing two or more independent polypeptide chains each of said chains comprising in a N- to C-terminus sequence:
- (1) an extracellular ligand association domain;
- (2) a transmembrane domain; and
- (3) one or more intracellular domains;
- provided that at least two of said domains in one chain are not naturally fused to each other.
2. DNA according to Claim 1 wherein each extracellular ligand association domain coded for is an antibody variable region (V_H or V_L) domain, a T-cell receptor variable region domain ($TCR\alpha$, $TCR\beta$, $TCR\gamma$, $TCR\delta$), $CD8\alpha$, $CD8\beta$, $CD11a$, $CD11b$, $CD11c$, $CD18$, $CD29$, $CD49a$, $CD49b$, $CD49c$, $CD49d$, $CD49e$, $CD49f$, $CD61$, $CD41$ or $CD51$ chain or a fragment thereof.
3. DNA according to Claim 2 wherein each association domain is structurally different to each other.
4. DNA according to Claim 1 wherein the ligand association domains of the chimeric receptor coded for are a V_H domain paired with a V_L domain, two or more $TCR\alpha$, $TCR\beta$, $TCF\gamma$, and/or $TCR\delta$ domains, a $CD8\alpha$ or β homo- or heterodimer, $CD18$ paired with one or more of $CD11a$, b , or c , $CD29$ paired with one or more of $CD49a$, b , c , d , e , or f , and $CD61$ paired with $CD41c$ and/or $CD51$.
5. DNA according to any of the preceding Claims wherein each intracellular domain coded for is a naturally occurring polypeptide signalling sequence.
6. DNA according to Claim 5 wherein each signalling sequence is all or part of the zeta, eta or epsilon chain derived from the T-cell receptor; $CD28$; $CD4$; $CD8$; the γ chain of a Fc receptor; a signalling component from a cytokine receptor, a colony stimulating factor

receptor, a tyrosine kinase and binding domains thereof; or an adhesion molecule .

- 5 7. DNA according to any one of Claims 1 to 6 wherein the transmembrane domain coded for is an oligo- or polypeptide derived from all or part of the alpha, beta or zeta chain of the T-cell receptor, CD28, CD8, CD4, CD3 ϵ , CD45 and members of the tetraspan family, a cytokine receptor, or a colony stimulating factor receptor.
- 10 8. DNA according to any one of Claims 1 to 7 wherein each independent polypeptide chain coded for additionally contains a spacer domain positioned between the ligand association domain and the transmembrane domain.
- 15 9. DNA according to Claim 8 wherein each spacer domain is a polypeptide comprising 20 to 100 amino acids.
- 20 10. DNA according to any one of Claims 1 to 9 wherein each independent polypeptide chain coded for additionally has a secretion signal sequence attached to the N-terminus of the association domain of each chain.
- 25 11. DNA according to any of the preceding Claims wherein the chimeric receptor coded for has two independent polypeptide chains.
- 30 12. DNA according to Claim 11 wherein one polypeptide chain has a ligand association domain which is a V_H domain or a fragment thereof, and the other has a ligand association domain which is a V_L domain or a fragment thereof.
- 35 13. DNA according to any one of Claims 1 to 12 in association with a carrier.
14. DNA according to Claim 13 wherein the carrier is a viral vector, a liposomal vector, a cationic lipid or an antibody.


15. DNA according to Claim 13 wherein the carrier is a targeted carrier.
16. DNA according to any one of Claims 1 to 15 which is located on a plasmid.
- 5 17. Plasmid pHMF374 as described in Figure 3 herein.
18. An effector cell containing DNA or a plasmid according to any one of Claims 1 to 17.
- 10

10/22/2000 10:44:30 AM


1/7

FIG. 1

Construct cassettes cloned into pBluescript KS+



Vh / CD8* / CD4TM / CD4



2/7

FIG. 2 OLIGONUCLEOTIDES SEQUENCES FOR
CHIMERIC RECEPTOR CONSTRUCTION

All oligos listed in the 5' to 3' orientation

S4501:CGCAAGCTTGCCGCCACCATGGAATGGAGC

S4502:TGGACTAGTTGAGGCAGAAGACACTGTCAC

S4503:CGCAAGCTTGCCGCCACCATGTCTGTCCC

S4504:TGGACTAGTCGTACGTTTTACTTCTACTTTAG

S4881:CGTGCCGGTCTTCCTGCCAGCGAAGCCCGGTGCGGGGCCAGCGCCG
CGACCACCAACACCGGCGCCCACCS4882:GAGGCGGCGCGGCCAGCGGCGGGGGCGCAGTGACACGAGGGGG
CTGGACTTCGCGGCCGCCCTGATTGTGS4883:CGCCGCTGGCCGCGCCGCCTCTGGGCGCAGGGACAGGGGGCTGCGAC
GCGATGGTGGGCGCCGGTGTTGGTGGS4884:CGCTGGCAGGAAGACCGGCACGAAGTGGCTGAAGTACATGATGG
AGTTGCTCAGGGCACTAGTTG

S4885:CAACTAGTGCCCTGAGCAACTCC

S4886:CACAATCAGGGCGGCCGCGAAG


S4499:CTGCAGTTCGCGGCCGCCCTGATTGTGCTGGGGGGCGTC

S4500:GCCGAGCTCCTATATGAATTCTCAAATGGGGCTACATGTCTTCTG


S4700:TATGAATTCTTAGCGAGGGGGCAGGGCCTGCATG

S4701:CTGGACTTCGCGGCCGCCCTGATTGTGCTGGGGGGCGTCGCCGGCC
TCCTGCTTTTCATTGGGCTAGGCATCTTCTTCAGAGTGAAGTTCAGCAGG
AGCGC


3/7



4/7




5/7




6/7

FIG. 4 STIMULATION OF SEPARATE CHAIN RECEPTORS WITH HL60 TARGET CELLS



7/7

FIG. 5 STIMULATION OF SEPARATE CHAIN RECEPTORS WITH NSO CELLS TRANSFECTED WITH A CONTROL PLASMID OR A CD33-EXPRESSING PLASMID



DECLARATION AND POWER OF ATTORNEY FOR PATENT APPLICATION

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below under my name.

I believe that I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled

CHIMERIC RECEPTORS

the Specification of which

☒ is attached hereto

☒ was filed on May 6, 1999

as International Application No. PCT/GB99/01417

I hereby state that I have reviewed and understand the contents of the above-identified Specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose information which is material to the examination of this application in accordance with Title 37, Code of Federal Regulations, 1.56(a).

I hereby claim foreign priority benefits under Title 35, United States Code, §119 (a)-(d) or § 365(b) of any foreign application(s) for patent or inventor's certificate, or §365(a) of any PCT international application which designated at least one country other than the United States of America, listed below and have also identified below, by checking the box, any foreign application for patent or inventor's certificate, or of any PCT international application having a filing date before that of the application on which priority is claimed.

<u>PRIOR FOREIGN FILED APPLICATION(S)</u>			
<u>APPLICATION</u> <u>NUMBER</u>	<u>COUNTRY</u>	<u>(MONTH/DAY/YYYY)</u>	<u>PRIORITY</u> <u>CLAIMED</u>
9809658.9	Great Britain	May 6, 1998	YES

I hereby claim the benefit under Title 35, United States Code §119(e) of any United States provisional application(s) listed below.

APPLICATION NUMBER(S)

FILING DATE (MM/DD/YYYY)

I hereby claim the benefit under Title 35, United States Code, §120 of any United States application(s), or §365(c) of any PCT international application designating the United States of America, listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States or PCT international application in the manner provided by the first paragraph of Title 35, United States Code §112, I acknowledge the duty to disclose information which is material to patentability as defined in Title 37, Code of Federal Regulations §1.56 which became available between the filing date of the prior application and the national or PCT international filing date of this application.

<u>U.S. Parent Application No.</u>	<u>PCT Parent Number</u>	<u>Parent Filing (MM/DD/YYYY)</u>	<u>Parent Patent Number (if applicable)</u>
--	------------------------------	---------------------------------------	---

The undersigned hereby authorizes the U.S. attorney or agent named herein to accept and follow instructions from **Carpmaels & Ransford** as to any action to be taken in the Patent and Trademark Office regarding this application without direct communication between the U.S. attorney or agent and the undersigned. In the event of a change in the persons from whom instructions may be taken, the U.S. attorney or agent named herein will be so notified by the undersigned.

I hereby appoint as my attorneys or agents the registered persons identified under

Customer No. 23565

for the law firm of Klauber & Jackson, said attorneys or agents with full power of substitution and revocation to prosecute this application and transact all business in the Patent and Trademark Office connected therewith.

Please address all correspondence regarding this application to **Customer No. 23565**.

DAVID A. JACKSON, ESQ.
KLAUBER & JACKSON
411 HACKENSACK AVENUE
HACKENSACK, NEW JERSEY 07601

Direct all telephone calls to David A. Jackson at (201) 487-5800.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further, that

these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

1-00
FULL NAME OF FIRST OR SOLE INVENTOR: Alastair David Griffiths LAWSON

COUNTRY OF CITIZENSHIP: Great Britain

FULL RESIDENCE ADDRESS: Holden Farm
Cheriton
Alresford
Hampshire
SO2 0NX
United Kingdom

G-BX

FULL POST OFFICE ADDRESS: SAME AS ABOVE

SIGNATURE OF INVENTOR Alastair David Griffiths Lawson

DATE 19/10/00

2-00
FULL NAME OF SECOND JOINT INVENTOR: Helene Margaret FINNEY

COUNTRY OF CITIZENSHIP: Great Britain

FULL RESIDENCE ADDRESS: 64 Clare Road
Maidenhead
Berkshire
SL6 4DQ
United Kingdom

G-BX

FULL POST OFFICE ADDRESS: SAME AS ABOVE

SIGNATURE OF INVENTOR Helene Margaret Finney

DATE 19.10.00